# Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

> **NCT06048926** · NA · ENROLLING_BY_INVITATION · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Carrelizumab
- **DRUG:** Paclitaxel injection
- **DRUG:** Cisplatin
- **RADIATION:** Concurrent chemoradiotherapy

## Key facts

- **NCT ID:** NCT06048926
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-07-30
- **Primary completion:** 2025-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048926, "Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06048926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*